Background Anti-NMDA receptor (NMDAR) encephalitis is an autoimmune disorder in which the use of immunotherapy and the long-term outcome have not been defi ned. We aimed to assess the presentation of the disease, the spectrum of symptoms, immunotherapies used, timing of improvement, and long-term outcome.
Introduction
In 2005, a syndrome with prominent psychiatric symptoms, memory loss, decrease of level of consciousness, and central hypoventilation was described in four young women with an ovarian teratoma and antibodies against an antigen highly expressed in the hippocampus. 1 Soon thereafter, the target antigen was identifi ed as the NMDA receptor (NMDAR). 2 The disorder, named anti-NMDAR enceph alitis, has since been seen in patients of all ages, but most often in young adults and children with or without teratomas. 3, 4 Findings from epidemiological studies suggest that this disorder is the most common cause of autoimmune encephalitis after acute demyelinating encephalomyelitis. 5 In a centre focused on the study of encephalitis of unclear cause (California Encephalitis Project, CA, USA), the frequency of anti-NMDAR enceph alitis surpassed that of any specifi c viral cause in young individuals. 6 Patients usually present with acute behav ioural change, psychosis, and catatonia that evolve to include seizures, memory defi cit, dyskinesias, speech problems, and autonomic and breathing dysregulation. 3 The syndrome resembles the phenotypes obtained with genetic and pharmacological decreases in expression and function of NMDAR. 7, 8 Findings from experiments in which patients' antibodies were added to cultures of hippocampal neurons or infused into the hippocampus of rodents showed specifi c antibody-mediated internalisation of NMDAR and alteration of the mechanisms of synaptic plasticity. 9, 10 Despite the severity of the disease, patients often improve after intensive care support, immunotherapy, and lengthy stays in hospital with multidisciplinary care. 3, 11 However, the eff ectiveness of immunotherapy and its long-term eff ect have not been established. Many patients do not respond to fi rst-line immunotherapy, such as steroids, plasmapheresis, and intravenous immunoglobulins, and for these patients the treatment strategy and outcome are unknown. Moreover, available evidence suggests that the syndrome and response to treatment can diff er between children and adults. 4 To address these issues, we assess the presentation of the disease, the spectrum of symptoms, immunotherapies used, timing of improve ment, and long-term outcome.
Methods

Study design and participants
In this observational cohort study, we tested for the presence of NMDAR antibodies in serum or CSF samples from patients at the hospitals of the University of Pennsylvania (Philadelphia, PA, USA) and the University of Barcelona (Spain), and from patients whose samples were sent to these institutions (from 200 centres in 35 coun tries; appendix) for study between Jan 1, 2007, and Jan 1, 2012 . Samples were recorded as positive if they fulfi lled previously reported criteria, 3 including a characteristic pattern of immuno staining of the neuropil of rat brain, and specifi c reactivity with HEK293 cells expressing GluN1 (also known as NR1) subunits of the NMDAR.
All patients who tested positive for NMDAR antibodies were included in the study without selection criteria other than availability of clinical information. Clinical information was obtained by the study investigators or referring physicians at the acute stage of the disease. On the basis of the reported manifestations of this disorder, 3 we categorised symptoms into eight groups: behaviour and cognition, memory, speech, seizures, movement disorder, loss of consciousness, autonomic dysfunction, and central hypoventilation. We defi ned children as patients younger than 18 years. Previous reports that suggested diff erences in symptom presentation and tumour association in children and adolescents 4 led us to examine these two features in three groups of patients: pre-pubertal (<12 years), post-pubertal (12-17 years), and adults (≥18 years). We obtained follow-up information at regular intervals after symptom onset (months 4, 8, 12, 18 , and 24); we assessed neurological status with the modifi ed Rankin scale (mRS). 12 We assessed results from only the fi rst MRI, electroencephalogram (EEG), and CSF examinations. All patients were screened at least once for systemic tumours. First-line immunotherapy was defi ned as the use of steroids, intravenous immunoglobulins, or plasma exchange alone or combined; second-line immunotherapy included rituximab or cyclo phosphamide alone or combined. There was no predefi ned protocol establishing the order or combination of treatments within each line of treatments. We recorded initial treatment as a failure if no sustained improvement occurred within 4 weeks after initiation of immunotherapy or tumour removal, and if the mRS score remained at 4 or higher. We excluded patients with a follow-up shorter than 4 months from analysis of eff ects of treatment and outcome. We defi ned relapse of encephalitis as the new onset or worsening of symptoms occurring after at least 2 months of improvement or stabilisation. Written consent for studies was obtained from families and patients' representatives; studies were approved by the institutional review boards of the University of Pennsylvania and the University of Barcelona.
Statistical analysis
We analysed demographic information and symptoms with Fisher exact, Fisher-Freeman-Halton test (an extension of the Fisher exact test for r × c contingency tables), or Mann-Whitney U test, as appropriate. Because of a skewed distribution, we used a log-transformation for age at symptom onset, duration of follow-up, and delay until initiation of treatment. For untreated patients, the last date of follow-up (maximum 24 months) was considered as the delay in initiation of treatment. Factors aff ecting outcome were assessed by univariable binary logistic regression (good outcome defi ned as mRS 0-2) independently of the treatments given. Factors asso ciated with a good outcome (p<0·1) were included in generalised linear mixed models with binary distribution, declaring the subject as random and the other factors as fi xed eff ects. 13 All mRS scores at defi ned timepoints were used (months 4, 8, 12, 18 , and 24; each patient's follow-up could provide a maximum of fi ve scores). We included time from onset of disease as an additional variable, allowing us to analyse patients with diff erent durations of follow-up. After creation of this model, we established the eff ect of second-line immunotherapy by adding second-line immunotherapy to the same model applied to only those patients who had failed fi rst-line immunotherapy. We analysed relapse frequency with Kaplan-Meier curves using log-rank statistics. We used SAS (version 9.3) for all multivariable analyses and SPSS (version 20) for all other analyses.
Role of the funding source
The study sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Overall, we included 577 patients in the demographic analyses (135 of whom seen by study investigators, all others seen by referring clinicians), of whom 501 had been followed-up for at least 4 months (median 24 months, range 4-186; fi gure 1 . 238 adults (65%) presented with behavioural problems, and 55 children (50%) younger than 12 years presented with seizures or movement disorders (fi gure 2). In adolescents, the frequencies of the indicated fi rst symptoms were in between those of young children and adults. The occurrence of abnormal behaviour, movement disorders, and seizures was diff erent between the three age groups (p<0·0001; fi gure 2) Within the fi rst 4 weeks of symptom onset, most patients developed a similar spectrum of symptoms irrespective of their age. Although movement disorders were more common in children, memory defi cits and central hypoventilation occurred more often in adults (fi gure 2). Atypical symptoms such as cerebellar ataxia or hemiparesis were more common in children than in adults. During the fi rst month of the disease, 498 (87%) of 571 patients developed four or more of the eight categories of symptom; only six patients (1%) had only one symptom (table 1). The assessment of disease severity showed that most patients had a maximum mRS score of 5 and were admitted to the intensive care unit (table 1) .
MRI, EEG, and CSF examinations were abnormal in 180 (33%) of 540 patients, 432 (90%) of 482 patients, and 418 (79%) of 532 patients, respectively. Detection of NMDAR antibodies was compared in 250 paired serum samples and CSF samples randomly selected by use of an online random integer generator, showing more sensitivity in CSF (100%) than serum (85%; p<0·0001; appendix).
In the 501 patients with at least 4 months follow-up, 462 (92%) were treated with fi rst-line immunotherapy, 134 (27%) with second-line im munotherapy (fi gure 1 and table 2), and 10 (2%) with tumour removal without immunotherapy, and 29 (6%) were not treated. The combination of fi rst-line immuno therapy most often used was steroids and intravenous immunoglobulins (202 [44%] patients). Of 197 patients with teratoma, 189 (96%) had tumour resection, 20 (11%) of them at neurological relapse or after recovery.
During the fi rst 24 months, 394 of 501 patients who had at least 4 months' follow-up had an mRS score of 0-2 Of the 472 patients who were treated with fi rst-line immunotherapy or tumour removal, about half had symptom improvement within 4 weeks of treatment (fi gure 1). During the fi rst 24 months, 241 of these patients had an mRS score of 0-2 (median 3 months, IQR 2-5); at 24 months' follow-up, 111 (97%) of 115 patients had a good outcome (fi gure 3). Of the 221 (47%) patients who had no improvement with these treatments, 125 (57%) received second-line immunotherapy and 96 (43%) had no further immunotherapy or continued receiving fi rst-line immunotherapy (fi gure 1).
Of the 125 patients who received second-line immunotherapy, 84 had an mRS score of 0-2 during the fi rst 24 months (median 10 months, IQR 6-21); in the 96 patients who did not receive second-line immunotherapy, 49 had an mRS score of 0-2 (median 15 months, IQR 7 to not achieved). At 24 month follow-up 43 (78%) of 55 patients who failed fi rst-line treatment and received second-line treatment and 32 (55%) of 58 patients who failed fi rst-line and not receive second-line treatment had a good outcome (fi gure 3). In multivariable analysis, we identifi ed the use of second-line immunotherapy as an additional factor for good outcome (table 3) . 29 patients were not treated with immunotherapy or surgery. The reasons for no treatment included fi rst diagnosis of the disease during relapses in 14 patients (initial episodes not treated), retrospective diagnosis in nine patients (four post mortem and fi ve with archived serum or CSF samples), and spontaneous improvement within a few weeks in six patients. Overall, in this group, 29% had a poor outcome (mRS 3-5 or dead).
During the 24 months' follow-up, 45 patients (a 12% risk) had clinical relapses, 15 (33%) of whom had multiple relapses (appendix). Compared with the initial episode, 46 (67%) of 69 relapses were less severe (as shown by a lower mRS score measured at the stage of maximum severity), more often mono-symptomatic (24 [35%] relapses), and re sulted in fewer admissions (12 [17%] relapses) to the intensive care unit (p<0·0001 for all). In 16 (23%) relapses, the severity of symptoms was similar to that of the patient's initial episode, but for seven (10%) relapses it was worse. Patients without a tumour had a higher frequency of relapses than did those with a tumour (p=0·0007), and the use of immunotherapy was asso ciated with fewer relapses (p=0·038; fi gure 4) Only 12 patients with teratoma identifi ed at symptom presentation or thereafter had neurological relapses (appendix).
The use of immunotherapy in the initial episode of encephalitis was associated with a lower frequency of relapses (p=0·038; fi gure 4 and appendix). Second-line immunotherapy was associated with fewer relapses in patients without tumour (p=0·007; appendix). Similarly, the introduction of second-line immunotherapy during relapses was associated with a decreased occurrence of subsequent relapses (p=0·024; appendix).
The time between symptom onset and initiation of treatment was shorter in children (all individuals younger than 18 years) than it was in adults (21 days [IQR 14-35] vs 28 days ; p=0·007; appendix). Overall, the outcome in children was much the same as that in adults (p=0·92; table 3 and appendix). In children, multivariable analysis identifi ed similar risk factors as those of adults (appendix). 81 (46%) of 177 children failed fi rst-line immunotherapy-in these patients, the magnitude of Data are n (%), unless otherwise stated. *Fisher's exact test, except for time from symptom onset, which is Mann-Whitney U test. †84% (n=85) of patients treated with weekly rituximab received four treatments of 375 mg/m², 8% (n=8) received fi ve to eight treatments; and 8% (n=8) received fewer than four treatments (in most cases two treatments of 500 mg/m² given 2 weeks apart); 73% (n=59) of patients treated with monthly cyclophosphamide received three to six treatment cycles of 750 mg/m², 15% (n=12) received seven to 12 cycles, and 12% (n=10) received one or two cycles. Four serious adverse events were reported including, one anaphylactic reaction and one infection due to rituximab, both causing a delay in treatment, and one infection and one severe lymphopenia due to cyclophosphamide causing discontinuation of this drug-no treatment-related deaths or irreversible complications were identifi ed. ‡Azathioprine, mycophenolate mofetil, tacrolimus, or methotrexate. §Eight patients with a tumour did not have surgery: six had teratomas and fi ve of them died of encephalitis; one was treated for an adenocarcinoma of the breast and the encephalitis improved; and one had a small-cell lung cancer and died. ¶12 patients failed fi rst-line therapies at relapse: seven without tumour had responded to fi rst-line therapies at initial episode, the other fi ve (one of them with a teratoma) did not have immunotherapy at their fi rst episode. 
Discussion
Our fi ndings show that immunotherapy and tumour removal, if applicable, result in substantial neurological improvement in 81% of patients with anti-NMDAR encephalitis after a median follow-up of 24 months Moreover, second-line immunotherapy with rituximab, cyclophosphamide, or both, improved the outcome of patients who did not respond to fi rst-line treatment and decreased the occurrence of relapses. Symptom presentation varied between children and adults (symptoms were more often neurological in children and more often psychiatric in adults), but in most cases the progression of symptoms evolved towards a similar syndrome. 1 month after disease onset, 87% of patients had four or more of the indicated groups of symptoms. Recognition of the combinations of these symptoms, which usually includes alter ation of cognition and behaviour (delusions, psychosis, catatonia) and abnormal movements (orofacial dyskin esias, choreoathetosis), should prompt testing for anti bodies against the GluN1 subunit of the NMDAR, especially in young people.
Identifi cation of NMDAR antibodies confi rms the diagnosis of the disorder and should lead to the search for a tumour, which, if present, is almost always an ovarian teratoma that contains nervous tissue and expresses NMDAR. 14, 15 Teratomas located elsewhere and other tumours are uncommon. In this study, the occur rence of an underlying teratoma was greater in female patients aged 12 years or older than it was in young children and male patients (52% vs 6%). Therefore, if a tumour is not detected, the extent and frequency of tumour screening should take into consideration a patient's age and sex. In female patients aged 12 years or older, a screening approach similar to that of para neoplastic syndromes is appropriate (eg, MRI of the abdomen and pelvis every 6 months for 4 years), 16 but in young children (<12 years) and male patients the need for repeat screening is unclear. If a tumour is detected, removal is important because it speeds up improvement and decreases relapses. 3, 17 Two independent predictors of good outcome were the lower severity of symptoms, assessed as no need for admission to an intensive care unit, and the prompt initiation of immunotherapy and tumour removal, if appropriate. A notable fi nding was the protracted phase of recovery that continued until the 18 months' follow-up. By establishing the last follow-up assessment at 24 months, our study probably underestimates the frequency and level of recovery because some patients had a shorter follow-up, others continued to improve after 24 months, and those with substantial improvement tended to discontinue follow-up (appendix). For the same reasons, our fi ndings have probably overestimated the occurrence of mortality; imputation analysis esti mated 7% mortality at 24 months (appendix).
Decisions about the type and duration of immunotherapy were made by referring physicians and were based on clinical symptoms, not antibody titres. 92% of patients underwent fi rst-line immunotherapy including steroids, intravenous immunoglobulins, and plasmapheresis alone or combined. This treatment and tumour removal, if applicable, resulted in improvement within the fi rst 4 weeks of treatment in 53% of patients, and 97% of them showed a good outcome at 24 months' follow-up (mRS score of 0-2). The main challenge was posed by the 47% of patients who did not improve with fi rst-line treatment within the fi rst 4 weeks of starting this treatment. These patients continued to have a poor mRS score (median score of 5). In this group, patients who received rituximab, cyclophos phamide, or both, had better outcomes than did those who continued with fi rst-line immunotherapy or who received no further immunotherapy. Similar results were obtained for paediatric patients; in this smaller group the eff ect of second-line immunotherapy was not statistically signifi cant but the estimated benefi t was similar to that of the entire cohort (ORs 3·35 vs 2·69). Second-line immuno therapy was well tolerated-only four patients had serious adverse eff ects, all of which were reversible (table 2) .
In this study, the eff ect of individual treatments (eg, plasma exchange vs intravenous immunoglobulins or rituximab) could not be compared side-by-side statistically. This is because the eff ect or lack of eff ect of a specifi c treatment directly aff ected physicians' decisions about additional treatment, leading to a paradox in which the more treatment a patient receives, the worse their outcome, but in fact the worse a patient is doing, the more treatment they receive. However, we could statistically assess the eff ect of the addition of second-line immunotherapy to patients whose symptoms were refractory to fi rst-line treatments.
Indeed, after failing fi rst-line immuno therapy, all these patients remained in a similar poor neurological status, enabling the comparison between those who subsequently received second-line immuno therapy with those who did not. The choice of adding second-line immunotherapy was based on the treating physician's preference, family acceptance of potential side-eff ects, and availability of the drugs. Although selection bias cannot be ruled out in observational studies like this one, we could not identify obvious bias between patients who after failing fi rst-line treatments were treated with second-line treatment and those who did not: the severity of symptoms (92% vs 88%) and duration of stay log e =natural logarithm. mRS=modifi ed Rankin scale.*An mRS score of 5 was the reference category. †To assess continuous improvement over time, the outcome at each individual timepoint was compared with that of the previous timepoint, with the p values indicated as well as the amount of events in those specifi c months after the previous timepoint. After 8 months the number of patients achieving good outcome (or events) becomes small (as refl ected in the large confi dence intervals). Patients improving from mRS 2 to 0 or 1 (or from 5 to 4 or 3) were not counted as events; these are all considered good outcome (or poor outcome), respectively. The 24-month follow-up is the reference value for the odds ratios (and the associated lower and higher range of the confi dence interval) of individual timepoints. in an intensive care unit (88% vs 87%) were much the same, and we recorded no diff erences in age, sex, ethnicity, and delay of initial immunotherapy. The lower frequency of neurological relapses (12% vs 20-24% reported in previous studies 11, 18 ) was probably caused by better recognition of the disorder, earlier treatment, and increasing use of second-line immunotherapy. Indeed, patients who received second-line immunotherapy during the initial episode of encephalitis had fewer relapses. Although this fi nding should be considered with caution because of the small number of patients, a similar eff ect was seen in patients who had previous relapses-in these patients the introduction of second-line immunotherapy reduced the occurrence of subsequent relapses. The presence of a teratoma not detected or untreated during the initial episode, or the possibility of tumour recurrence, should be considered in patients with a relapse. In panels A and B, the total number of patients at baseline is 513 instead of 577 because for some patients no follow-up was available. The number at risk at 4 months' follow-up is 489 and not 501 because some patients had already had a relapse (event).
Panel: Research in context
Systematic review
We searched Medline and Embase up until Oct 01, 2012, for articles published in any language with the search terms "Anti-N-Methyl-D-Aspartate Receptor Encephalitis", "Receptors, N-Methyl-D-Aspartate", and "Encephalitis". We restricted searches to studies in human beings. We also reviewed the reference lists of the papers identifi ed by this search. We identifi ed ten studies and one extended review describing at least three patients; fi ve of the studies included at least 25 patients.
Interpretation
Our study extends epidemiological and clinical knowledge on anti-NMDA receptor encephalitis. It lends support to the female preponderance, the high frequency of the disease in children, and a higher risk for an underlying teratoma in black people. The higher frequency of teratomas in Asian patients is a novel fi nding. The fi ndings suggest that the clinical presentation in children is often diff erent from that in adults; this fi nding has been previously suggested in small series but not substantiated until now. In this study, the occurence of relapses was less frequent than in previous reports. Additionally, the less severe nature of the symptoms compared with the initial episodes was noted in most relapses. To our knowledge, this is the fi rst study to provide extensive and structured follow-up and prognostic factors that aff ect outcome. The suggested better outcome of patients with teratoma compared with those without teratoma was not confi rmed in this study; however, we identifi ed stay in an intensive care unit and the time from symptom onset to initiation of treatment as important prognostic factors. First-line immunotherapy was often insuffi cient to control the disease; in this group of patients, the addition of second-line immunotherapy was associated with a better outcome compared with those who did not receive second-line immunotherapy.
The discovery of anti-NMDAR encephalitis has changed the diagnostic and treatment approach to several neurological and psychiatric disorders, and has led to the identifi cation of an expanding group of autoimmune encephalitis related to antibodies against synaptic proteins.
19 Rapidly progressive alterations of memory, behaviour, cognition, and psychosis previously thought to be idiopathic or virally induced are now known to be autoimmune (panel). [20] [21] [22] [23] To our knowledge, a systematic analysis of the eff ects of sequential (fi rst-line, second-line) immunotherapy and their eff ect on long-term outcome has not been previously done in any of these disorders or other antibody-mediated neurological diseases.
Our study has the limitations of not being randomised, but it is precursory to future trials to establish the effi cacy of each individual treatment (eg, steroids, intravenous immunoglobulins, plasmapheresis, rituximab, and cyclophosphamide) and duration of immunotherapy. Moreover, the large number of events (patients achieving a good outcome) and prospective follow-up of many patients reported in this study, provide level II-2 evidence 24 of the usefulness of immunotherapy and tumour removal in anti-NMDAR encephalitis.
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